Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Dequalinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dequalinium SCHEMBL29613054 | 1.00 | MEN1 (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| Dequalinium SCHEMBL34043 | 1.00 | MEN1 (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| Dequalinium SCHEMBL2544854 | 1.00 | MEN1 (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| Dequalinium SCHEMBL3967999 | 0.98 | MEN1 (0.97) | MEN1GMNNLMNAPOLBMAPT | |
| SCHEMBL6299633 | 0.98 | PRKCA (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| SCHEMBL6298118 | 0.98 | PRKCA (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| Dequalinium SCHEMBL29577841 | 0.98 | PRKCA (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| Dequalinium SCHEMBL149457 | 0.98 | PRKCA (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| Dequalinium SCHEMBL29557297 | 0.98 | PRKCA (1.00) | MEN1GMNNLMNAPOLBMAPT | |
| SCHEMBL6305111 | 0.98 | PRKCA (1.00) | MEN1GMNNLMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747302-A2 | REPAIR AND OPTIMIZATION OF NANOCOMPOSITE MATERIALS | Nanocore ApS (DK) | 2026-05-27 | — | — | EP | claimed |
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | INNOBATION BIO CO LTD (KR) | 2026-04-30 | — | — | US | claimed |
| EP-4719411-A2 | QUINOLINEAMINE AND PYRIDOQUINOLINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF | Flexsys IP Holdings, LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4532035-B1 | GRANULES OF CLAY-BASED ANTIMICROBIAL PARTICLES | UNILEVER IP HOLDINGS B V (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-4704835-A2 | ANTIDEGRADANT BIS(DIHYDRO AND TETRAHYDROQUINOLINE) COMPOUNDS AND USES THEREOF | Flexsys IP Holdings, LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4532036-B1 | SPHERICAL GRANULES OF CLAY-BASED ANTIMICROBIAL PARTICLES | UNILEVER IP HOLDINGS B V (NL) | 2026-03-04 | — | — | EP | claimed |
| EP-4687882-A2 | 6-AMINOQUINOLINE ANTIDEGRADANTS | Flexsys IP Holdings, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4687881-A2 | HETEROARYL ANTIDEGRADANTS | Flexsys IP Holdings, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4676471-A2 | QUINOLINEIMINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF | Flexsys IP Holdings, LLC (US) | 2026-01-14 | — | — | EP | claimed |
| US-12493041-B2 | Apparatus for diagnosing solid cancers and method for providing information on solid cancer diagnosis | INNOBATION BIO CO., LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| US-20230031378-A1 | SOLID ELECTROLYTE SEPARATOR BONDING AGENT | QUANTUMSCAPE BATTERY, INC. | 2023-02-02 | — | — | US | claimed |
| WO-2023277945-A1 | LITHIUM ION BATTERY WITH COMPOSITE ELECTRODES | GOOGLE LLC (US) | 2023-01-05 | — | — | WO | claimed |
| EP-3113843-B1 | COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING | TUFFLEY MARK (AU) | 2022-12-14 | — | — | EP | claimed |
| US-20220349895-A1 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | INNOBATION BIO CO., LTD. (KR) | 2022-11-03 | — | — | US | claimed |
| US-11450926-B2 | Solid electrolyte separator bonding agent | QUANTUMSCAPE BATTERY, INC. (US) | 2022-09-20 | — | — | US | claimed |
| EP-4027139-A2 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | Innobation Bio Co., Ltd. (KR) | 2022-07-13 | — | — | EP | claimed |
| CN-114456227-A | Technetium-99 m labeled D-proline-containing glycine polypeptide modified FAPI derivative, and preparation method and application thereof | 北京师范大学 | 2022-05-10 | — | — | CN | claimed |
| WO-2022072394-A1 | CURABLE COATING COMPOSITIONS AND ANTIMICROBIAL/ANTIVIRAL COATINGS MADE BY CURING SUCH COATING COMPOSITIONS | GREEN THEME TECHNOLOGIES, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| US-20220098418-A1 | CURABLE COATING COMPOSITIONS AND ANTIMICROBIAL COATINGS MADE BY CURING SUCH COATING COMPOSITIONS | GREEN THEME TECHNOLOGIES, INC. | 2022-03-31 | — | — | US | claimed |
| US-11285179-B2 | Method for preventing or treating movement disorders with lactic acid bacterium | BENED BIOMEDICAL CO., LTD. (TW) | 2022-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | KYNU, CPT2, CPT1A | CHRM2 1008/4885CHRM1 1232/4885ACHE 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.